# US 2026/0209313 A1 · Laminin extraction, purification and polymerization processes, use, polylaminin and kit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209313 A1
- Document ID: US20260209313A1
- Status: Published application
- Kind: A1
- Application number: 19/141,997
- Filed: 2023-12-19
- Published: 2026-07-23
- Earliest claimed: 2022-12-21
- Assignees: Cristalia Produtos Quimicos Farmaceuticos Ltda.
- Applicants: CristáLia Produtos QuíMicos FarmacêUticos Ltda.
- Inventors: Ogari de Castro PACHECO; Francesco Brugnera TEIXEIRA; German Enrique WASSERMANN; Aline Hunger RIBEIRO
- Web page: https://patentgrep.com/patent/US20260209313A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B01D 15/362: {Cation-exchange}
- B01D 15/424: {Elution mode}
- C07K 1/18: Ion-exchange chromatography
- C07K 1/303: {by salting out}
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 25/00: Drugs for disorders of the nervous system
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Process for extraction and purification of laminins from human placenta, with preserved acid polymerization capacity to generate polylaminin, are described. The process of acid polymerization of purified laminins, the use of purified laminins in the manufacture of polylaminin pharmaceutical compositions, as well as a kit for extemporaneous preparation of said compositions, wherein the compositions and kit are suitable for the therapy of central nervous system injuries, mainly spinal cord injuries, are also described.

## Claims

### Claim at position 1

1-51. (canceled)

### Claim 52

A process for extracting laminin from human placenta to obtain a laminin-rich protein extract comprising:
(i) processing the placenta to remove unwanted elements, and washing to obtain clean placental tissue;
(ii) homogenizing the clean placental tissue and separating homogenized tissue from the resulting fluids;
(iii) extracting laminins from the homogenized placental tissue in extraction buffer consisting of 50 mM Tris, 1.0 M NaCl, 10 mM EDTA and having pH 7.4, under slow stirring, wherein the buffer volume and the placental tissue mass are in 2:1 ratio;
(iv) optional filtration; and
(v) selectively precipitating laminins in solution resulted from step (iii) or (iv) by salting out with ammonium sulfate salt at a saturating concentration of 30% to obtain a laminin-rich protein extract;
wherein step (i) does not require removal of the chorion from the placental tissue and wherein the process is carried out in the absence of protease inhibitors.

### Claim 53 (depends on 52)

The process, according to claim 52, that is carried out using placenta frozen at −20° C. and further comprising thawing of the frozen placenta.

### Claim 54 (depends on 53)

The process, according to claim 53, wherein the placenta is quickly thawed at room temperature.

### Claim 55 (depends on 52)

The process according to claim 52, wherein the washing in step (i) is carried out with an ice-cold physiologically acceptable liquid.

### Claim 56 (depends on 52)

The process according to claim 52, wherein homogenization in step (ii) is carried out in an industrial blender with a physiologically acceptable liquid.

### Claim 57 (depends on 52)

The process according to claim 52, wherein in step (ii) the homogenized tissue is separated from the resulting fluids by centrifugation.

### Claim 58 (depends on 52)

The process according to claim 52, wherein filtration in step (iv) is carried out through a depth filter.

### Claim 59

A process for purifying laminins from a human placenta laminin-rich protein extract comprising:
(a) solubilizing human placenta laminin-rich protein extract in a resuspension buffer in the presence of a chaotropic agent;
(b) cation exchange chromatography which is employed as the only ion exchange chromatographic step in the process; and
(c) molecular exclusion chromatography to obtain purified laminins.

### Claim 60 (depends on 59)

The process according to claim 59, wherein the human placenta laminin-rich protein extract is obtained by the process comprising:
(i) processing the placenta to remove unwanted elements, and washing to obtain clean placental tissue;
(ii) homogenizing the clean placental tissue and separating homogenized tissue from the resulting fluids;
(iii) extracting laminins from the homogenized placental tissue in extraction buffer consisting of 50 mM Tris, 1.0 M NaCl, 10 mM EDTA and having pH 7.4, under slow stirring, wherein the buffer volume and the placental tissue mass are in 2:1 ratio;
(iv) optional filtration; and
(v) selectively precipitating laminins in solution resulted from step (iii) or (iv) by salting out with ammonium sulfate salt at a saturating concentration of 30% to obtain a laminin-rich protein extract;
wherein step (i) does not require removal of the chorion from the placental tissue and wherein the process is carried out in the absence of protease inhibitors such as pheny-methylsulfonyl fluoride and N-ethyl-maleimide.

### Claim 61 (depends on 59)

The process according to claim 59, wherein in step (a) the chaotropic agent is urea.

### Claim 62 (depends on 59)

The process according to claim 59, wherein in step (a) the resuspension buffer is 20 mM tris, containing 2 M urea and pH 7.5.

### Claim 63 (depends on 59)

The process according to claim 59, wherein cation exchange chromatography is carried out with a resin that is a cross-linked copolymer of allyl dextran and N,N-methylene bisacrylamide, or a cross-linked agarose matrix or a membrane of stabilized reinforced cellulose.

### Claim 64 (depends on 59)

The process according to claim 59, wherein in step (b) cation exchange chromatography is carried out with resin functionalized with sulfopropyl (SP) or methylsulfonate(S) groups.

### Claim 65 (depends on 59)

The process according to claim 59, wherein in step (b) elution of the laminin fraction is carried out with an ionic strength gradient.

### Claim 66 (depends on 59)

The process according to claim 59, wherein in step (b) cation exchange chromatography is carried out with resin functionalized with sulfopropyl groups (SP), in which the material introduced into the column has a conductivity of 7 mS/cm and the elution of the laminin fraction occurs with an increase in the conductivity of the eluent to a range between 14.0 and 14.1 mS/cm by NaCl addition.

### Claim 67 (depends on 59)

The process according to claim 59, wherein molecular exclusion chromatography resin has pores with a nominal separation range of 5 to 5,000 kDa.

### Claim 68 (depends on 59)

The process according to claim 59, further comprising step d), wherein the laminins are concentrated using a concentrator with a cutoff of 30 kDa or 50 kDa.

### Claim 69 (depends on 59)

A kit for the extemporaneous preparation of a polylaminin pharmaceutical composition for use in the treatment of spinal cord injury and central nervous system injuries, comprising a first vial that contains purified laminins obtained by the purification process as defined by claim 59, and a second vial that comprises an acidic preparation.

### Claim 70 (depends on 69)

The kit according to claim 69, wherein the acidic preparation additionally comprises an osmolality adjusting agent.

### Claim 71 (depends on 69)

The kit, according to claim 69, that further comprises a preparation of divalent cations.
